HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

8.130

-0.170-2.05%

Volume:2.29M

Turnover:18.70M

Market Cap:4.21B

PE:-13.13

High:8.280

Open:8.250

Low:8.005

Close:8.300

52wk High:96.900

52wk Low:8.005

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:1.88

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.619

ROE:-19.61%

ROA:-9.68%

PB:2.78

PE(LYR):-13.13

PS:34.88

Loading ...

Overview Company News Filings

Xuanzhu Biopharma Interim 2026: Revenue Jumps 288.10%, Net Loss Contracts 32.10%

Bulletin Express

Xuanzhu Biopharmaceutical Keeps Share Base Unchanged in August 2026 and Meets Public-Float Requirement

Bulletin Express

Xuanzhu Biopharm seals exclusive Thailand deal with Innobic for Bireociclib commercialisation through 2036

Bulletin Express

Sihuan Pharma Affiliate Xuanzhu Biopharm Grants Innobic Exclusive Thailand Commercialization Rights for Bireociclib Tablets

XUANZHUBIO-B Partners with INNOBIC to Commercialize Pyrotinib in Thailand

Xuanzhu Biopharmaceutical Co - Announces Commercial Cooperation with Innobic for Birecociclib in Thailand

THOMSON REUTERS

Xuanzhu Biopharmaceutical Co - Grants Exclusive Commercialisation Rights for Birecociclib in Thailand to Innobic (Asia) and Zaoan International

THOMSON REUTERS

Hong Kong Stock Market Pulse | XUANZHUBIO-B (02575) Surges Over 5% Pre-Noon as H1 Revenue Jumps 288.1% on Dual Licensing and In-Licensing Momentum

Xuanzhu Biopharmaceutical (SEHK:2575) Stock Still Carries A Lofty P S Burden

Simply Wall St.

Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead

Xuanzhu Biopharmaceutical: Hy Loss Attributable Rmb75.3 Mln

THOMSON REUTERS

Xuanzhu Biopharmaceutical Co Ltd - ‍Does not Recommend the Payment of an Interim Dividend

THOMSON REUTERS

XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release

We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate

Simply Wall St.

Xuanzhu Biopharmaceutical Sets Board Meeting to Review Interim Results

Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award

Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement

Bulletin Express

XUANZHUBIO-B gains NMPA NDA acceptance for Anaprazole Sodium to treat reflux esophagitis

Bulletin Express

Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis

Xuanzhu Biopharmaceutical Co - Nmpa Accepts Nda for Anaprazole Sodium for Reflux Esophagitis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/02575/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":8.13,"timestamp":1789546126004,"preClose":8.3,"halted":0,"volume":2286500,"delay":0,"changeRate":-0.020481927710843364,"floatShares":517947790,"shares":518000000,"eps":-0.6193021103004629,"marketStatus":"Not Yet Opened","change":-0.17,"latestTime":"09-16 16:08:46","open":8.25,"high":8.28,"low":8.005,"amount":18703215,"amplitude":0.033133,"askPrice":8.15,"askSize":500,"bidPrice":8.13,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":-0.4921173212520593,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":8.3,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":1.87843,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.619302,"volumeRatio":1.87843,"shares":518000000,"dividePrice":0,"high":8.28,"amplitude":0.033133,"preClose":8.3,"low":8.005,"week52Low":8.005,"pbRate":"2.78","psRate":"34.88","week52High":96.9,"institutionHeld":0,"latestPrice":8.13,"committee":0.857143,"eps":-0.6193021103004629,"divideRate":0,"volume":2286500,"delay":0,"ttmEps":-0.4921173212520593,"open":8.25,"prevYearClose":70.5,"prevWeekClose":8.94,"prevMonthClose":10.08,"prevQuarterClose":13.33,"fiveDayClose":9.565,"twentyDayClose":11.33,"sixtyDayClose":15.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-09-15","current":-16.507079,"percent":1,"low":-70.039607,"twenty":-54.987648,"median":-41.037619,"eighty":-23.553335,"high":-17.52948,"avg":-40.640787,"sd":14.683709,"marketCap":4298966657},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140},{"date":"2026-09-04","current":-22.054147,"twenty":-55.10047,"median":-42.591003,"eighty":-24.406781,"marketCap":5402195449},{"date":"2026-09-11","current":-18.878079,"twenty":-55.025187,"median":-41.829865,"eighty":-23.78146,"marketCap":4630453242},{"date":"2026-09-15","current":-17.52948,"twenty":-54.987648,"median":-41.037619,"eighty":-23.553335,"marketCap":4298966657}],"updateTime":1789562031916},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140600787","title":"Xuanzhu Biopharma Interim 2026: Revenue Jumps 288.10%, Net Loss Contracts 32.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140600787","media":"Bulletin Express","labels":["dataReport","SGX"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1140600787?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:18","pubTimestamp":1789550286,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. released its unaudited interim results for the six months ended 30 June 2026. Revenue rose to RMB 69.44 million, an increase of 288.10% year-on-year, driven by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Xuanzhu Biopharma Interim 2026: Revenue Jumps 288.10%, Net Loss Contracts 32.10%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128134753","title":"Xuanzhu Biopharmaceutical Keeps Share Base Unchanged in August 2026 and Meets Public-Float Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=1128134753","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128134753?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:43","pubTimestamp":1788522238,"startTime":"0","endTime":"0","summary":"For the month ended 31 August 2026, Xuanzhu Biopharmaceutical Co., Ltd. reported no changes in its share capital structure. Issued H-shares remained at 517.95 million, each with a par value of RMB 1,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167309370","title":"Xuanzhu Biopharm seals exclusive Thailand deal with Innobic for Bireociclib commercialisation through 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=1167309370","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167309370?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:25","pubTimestamp":1788427515,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm; stock name: XUANZHUBIO-B) has entered into a tri-party commercial agreement with Thailand-based Innobic (Asia) Co., Ltd. and Hong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878574","title":"Sihuan Pharma Affiliate Xuanzhu Biopharm Grants Innobic Exclusive Thailand Commercialization Rights for Bireociclib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878574","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878574?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:18","pubTimestamp":1788427127,"startTime":"0","endTime":"0","summary":"Sihuan Pharma affiliate Xuanzhu Biopharm grants Innobic exclusive Thailand commercialization rights for Bireociclib tabletsSihuan Pharmaceutical’s non-wholly owned unit Xuanzhu Biopharm granted exclus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL8K9jwT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191","BK1593","BK1600","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109166923","title":"XUANZHUBIO-B Partners with INNOBIC to Commercialize Pyrotinib in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=1109166923","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109166923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:18","pubTimestamp":1788427123,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced a tripartite commercial agreement with Thai pharmaceutical firm Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. for its pyrotinib tablets, valid...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878348","title":"Xuanzhu Biopharmaceutical Co - Announces Commercial Cooperation with Innobic for Birecociclib in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878348?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:13","pubTimestamp":1788426788,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487831","title":"Xuanzhu Biopharmaceutical Co - Grants Exclusive Commercialisation Rights for Birecociclib in Thailand to Innobic (Asia) and Zaoan International","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487831","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487831?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:13","pubTimestamp":1788426788,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1D6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123959722","title":"Hong Kong Stock Market Pulse | XUANZHUBIO-B (02575) Surges Over 5% Pre-Noon as H1 Revenue Jumps 288.1% on Dual Licensing and In-Licensing Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1123959722","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123959722?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:42","pubTimestamp":1788406936,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares climb more than 5% during the morning trading session, last up 5.42% at HK$9.915, with turnover reaching HK$2.7797 million.The company released its interim results...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575","VXUS","BK4588","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662726707","title":"Xuanzhu Biopharmaceutical (SEHK:2575) Stock Still Carries A Lofty P S Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2662726707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662726707?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:25","pubTimestamp":1787829933,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical stock has been under pressure, with the share price down about 5% over the past week and more than 35% over three months. Yet the latest half year results tell a more nuanced story. Revenue for H1 2026 reached ¥69.441 million and the loss narrowed to ¥75.34 million, which softened basic earnings per share to a loss of ¥0.15.\nThe real flashpoint for sentiment is valuation. Xuanzhu trades on a P/S ratio of 45.4x, which is far above the Hong Kong pharmaceuticals...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/xuanzhu-biopharmaceutical-sehk2575-stock-still-carries-a-lof","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/xuanzhu-biopharmaceutical-sehk2575-stock-still-carries-a-lof","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154655464","title":"Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=1154655464","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154655464?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:07","pubTimestamp":1787717221,"startTime":"0","endTime":"0","summary":"Hong Kong's benchmark index kicked off the morning session with a 0.68% gain, advancing 174 points to reach 25,685 points, while the tech-heavy Hang Seng Tech Index climbed a more robust 1.58%....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1568","LU0052750758.USD","IE00B5MMRT66.SGD","LU1720050803.USD","601995","688185","MCHmain","LU0348783233.USD","LU0348767384.USD","LU1794554557.SGD","03908","07500","SG9999014674.SGD","BK1227","03067","BK1513","LU0540923850.HKD","603993","03033","LU0607220059.USD","LU0359201885.HKD","LU0561508036.HKD","LU0417516902.SGD","HSI","02837","06166","BK1564","03037","LU0348784397.USD","07552","HSImain","09115","LU0181495838.USD","603083","LU0862451837.USD","03115","BK1589","BK1233","BK1242","KURE","LU0463099449.HKD","LU0405327494.USD","LU2351347302.SGD","LU0594300419.USD","LU1880383440.USD","IE00BMCWC346.EUR","LU1880383366.USD","LU1961090484.USD","BK1516","HK0000286598.CNH","03993","HSTECH","LU0634319403.HKD","LU0326950275.SGD","LU1188198961.HKD","IE00BGHQDM52.EUR","BK1521","600362","LU0359202008.SGD","BK1149","09088","600999","BK1237","LU0890818403.SGD","LU2399975544.HKD","02833","09067","IE00B543WZ88.USD","LU1023057109.AUD","LU0594300179.USD","LU0149721374.USD","LU2476274720.SGD","LU0862451753.SGD","03423","IE00BZ08YS42.EUR","LU1048596156.SGD","01112","LU0348735423.USD","LU2476274308.USD","LU0417516738.SGD","LU1102505929.USD","06831","07300","LU2187417386.USD","03032","LU2929501877.USD","01828","IE0031814852.USD","IE00B031HY20.USD","IE00BVYPNQ40.USD","BK1206","IE00B29SXG58.USD","07200","LU0359201612.USD","BK1501","LU0417516571.SGD","IE00BPRC5H50.USD","IE0008369823.USD","LU0348825331.USD","LU2778985437.USD","03088","09926","BK1240","BK1190","BK1184","06099","LU2125910500.SGD","SG9999004220.SGD","BK1574","BK1553","82800","02313","LU0164880469.USD","LU0605514214.HKD","SG9999004311.SGD","BK1594","BK1580","LU1328277881.USD","LU0405327148.USD","LU0650527681.SGD","LU0320764599.SGD","IE00BVYPNP33.GBP","LU1481107354.HKD","BK1592","LU0708995583.HKD","IE00B031J352.USD","SG9999002828.SGD","06185","LU0821914370.USD","LU0828237940.HKD","LU0244354667.USD","BK1191","LU0348766576.USD","HTImain","02800","06969","LU0348827113.USD","513600","02575","SG9999002950.SGD","IE00BYV24P56.USD","LU2488822045.USD","HHImain","LU2039709279.SGD","BK1515","LU2045819591.USD","01258","LU2213484517.USD","BK1147","LU0314109678.HKD","03417","00358","LU0140636845.USD","IE00BZ08YR35.GBP","03419","07226","83115","IE0008368742.USD","LU1102505762.USD","LU0149534421.HKD","LU1813983027.USD","IE00BZ08YT58.USD","BK1161","LU1831875114.USD","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764154","title":"Xuanzhu Biopharmaceutical: Hy Loss Attributable Rmb75.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662764154?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:02","pubTimestamp":1787716978,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXLQ91WS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764158","title":"Xuanzhu Biopharmaceutical Co Ltd - ‍Does not Recommend the Payment of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662764158?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:02","pubTimestamp":1787716931,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXBQ1N0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169961354","title":"XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1169961354","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169961354?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:50","pubTimestamp":1787712647,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479250","title":"We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479250","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479250?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:56","pubTimestamp":1787180214,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/were-not-very-worried-about-xuanzhu-biopharmaceuticals-hkg25","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/were-not-very-worried-about-xuanzhu-biopharmaceuticals-hkg25","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155279","title":"Xuanzhu Biopharmaceutical Sets Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155279?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:57","pubTimestamp":1786618663,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical sets board meeting to review interim resultsXuanzhu Biopharmaceutical will hold a board meeting on Aug. 26, 2026.Directors will review interim results for the six months ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3w6dBz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","BK1191","00460","02575","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652377251","title":"Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2652377251","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652377251?lang=en_us&edition=fundamental","pubTime":"2026-07-19 18:49","pubTimestamp":1784458150,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration awardXuanzhu Biopharmaceutical received a final CIETAC arbitration award on July 15, 2026 over a May 21, 2021 technology transfe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nNDL9lltbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191","BK1515","BK1600","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126665105","title":"Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=1126665105","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126665105?lang=en_us&edition=fundamental","pubTime":"2026-07-07 17:06","pubTimestamp":1783415163,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124964143","title":"XUANZHUBIO-B gains NMPA NDA acceptance for Anaprazole Sodium to treat reflux esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1124964143","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124964143?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:43","pubTimestamp":1782794605,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B) has received formal acceptance from China’s National Medical Products Administration (NMPA) for its New Drug Application covering a new...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581790","title":"Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581790","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647581790?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792352,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisXuanzhu Biopharmaceutical’s NMPA accepted an NDA for anaprazole sodium enteric-coated tablets to treat adult reflux e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2BC18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","02575","BK1515","BK1191","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647736581","title":"Xuanzhu Biopharmaceutical Co - Nmpa Accepts Nda for Anaprazole Sodium for Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647736581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647736581?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792343,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN43116P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":84,"code":"91000000","status":"200"}]}}